medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2021-14-96-103medsovet-6433Research ArticleКОМОРБИДНЫЙ ПАЦИЕНТCOMORBID PATIENTАнализ качества жизни пациентов с сахарным диабетом 1-го типа, получавших инсулин деглудек, в реальной клинической практикеAnalysis of the quality of life of patients with type 1 diabetes mellitus in real clinical practice who received insulin degludechttps://orcid.org/0000-0001-9253-8075СуплотоваЛ. А.SuplotovaL. A.

Суплотова Людмила Александровна, д.м.н., профессор, заведующая курсом эндокринологии кафедры терапии с курсами эндокринологии, функциональной и ультразвуковой диагностики

625000, Тюмень, ул. Одесская, д. 54

Lyudmila A. Suplotova, Dr. Sci. (Med.), Professor, Head of the Course of the Endocrinology, Department of Therapy with Courses of Endocrinology, Functional and Ultrasound Diagnostics

54, Odesskaya St., Tyumen, 625000

suplotovala@mail.ruhttps://orcid.org/0000-0002-1932-1686СудницынаА. С.SudnitsynaA. S.

Судницына Анна Сергеевна, аспирант кафедры терапии с курсами эндокринологии, функциональной и ультразвуковой диагностики; врач-эндокринолог

625000, Тюмень, ул. Одесская, д. 54

625023, Тюмень, ул. Котовского, д. 55

Anna S. Sudnitsyna, Postgraduate Student of the Department of Therapy with Courses of Endocrinology, Functional and Ultrasound Diagnostics; Endocrinologist

54, Odesskaya St., Tyumen, 625000

55, Kotovskiy St., Tyumen, 625023

dr.sudnitsyna@mail.ruhttps://orcid.org/0000-0001-7124-1176РомановаН. В.RomanovaN. V.

Романова Наталья Валерьяновна, к.м.н., заведующая эндокринологическим отделением

625039, Тюмень, ул. Мельникайте, д. 75

Natalia V. Romanova, Cand. Sci. (Med.), Head of the Endocrinology Department

75, Melnikayte St., Tyumen, 625039

n.v.romanova2014@yandex.ruТюменский государственный медицинский университетРоссияTyumen State Medical UniversityRussian FederationТюменский государственный медицинский университет; Областная клиническая больница № 1РоссияTyumen State Medical University; Regional Clinical Hospital No. 1Russian FederationОбластная клиническая больница № 2РоссияRegional Clinical Hospital No. 2Russian Federation20211710202101496103Copyright © Суплотова Л.А., Судницына А.С., Романова Н.В., 20212021Суплотова Л.А., Судницына А.С., Романова Н.В.Suplotova L.A., Sudnitsyna A.S., Romanova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/6433

Введение. Долгосрочный и качественный гликемический контроль предотвращает развитие сосудистых осложнений сахарного диабета (СД) 1-го типа и улучшает прогноз заболевания, существенно увеличивая продолжительность жизни. Снижение качества жизни (КЖ) пациентов с СД 1-го типа ассоциировано с развитием осложнений СД, состоянием углеводного обмена. В связи с доказанными преимуществами использования показателей времени нахождения в диапазонах гликемии (TIR, TAR, TBR) изучение их ассоциаций с КЖ пациентов с СД 1-го типа при переходе с аналоговых инсулинов длительного действия на инсулин деглудек представляет особый интерес.Цель. Оценить качество жизни пациентов с сахарным диабетом 1-го типа при переводе с аналогов длительного действия на инсулин деглудек в условиях реальной клинической практики.Материалы и методы. Исследование спланировано как проспективное, одноцентровое, неконтролируемое. Набор пациентов с СД 1-го типа, не достигших целевых значений контроля углеводного обмена, находящихся на терапии аналоговыми инсулинами длительного и ультракороткого действия, осуществлялся по критериям соответствия. Расчет TIR, TAR, TBR проводился на основании данных профессионального непрерывного мониторирования уровня глюкозы и самоконтроля уровня глюкозы крови. Для оценки КЖ использовался опросник Health Status Survey SF-36.Результаты. В  исследование вошли 26  пациентов, которые соответствовали критериям включения и  не  имели критериев исключения. Выявлены взаимосвязи TIR и TBR с параметрами КЖ на фоне терапии инсулином деглудек: с жизненной активностью, интенсивностью боли, параметром психического здоровья, что демонстрирует повышение КЖ преимущественно за счет психологического компонента здоровья.Выводы. Перевод пациентов с СД 1-го типа с аналоговых инсулинов длительного действия на аналоговый инсулин сверхдлительного действия в  амбулаторных условиях обеспечивает улучшение гликемического контроля за  счет HbA1c и TIR, TBR, а также повышает удовлетворенность КЖ преимущественно за счет психологического компонента здоровья.

Introduction. Long-term and high-quality glycemic control prevents the development of vascular complications of diabetes type 1 and improves the disease prognosis, significantly increasing life expectancy. A decrease in the quality of life (QOL) of patients with diabetes type 1 is associated with the disease complications development and carbohydrate metabolism status. In connection with the proven advantages of using indicators of time spent in glycemic ranges (TIR, TAR, TBR), the study of their associations with QOL in patients with type 1 diabetes when switching from long-acting analog insulins to insulin degludec is of particular interest.Aims. To assess the quality of life with diabetes type 1 when switching from long-acting analogs to insulin degludec in real world clinical practice.Materials and methods. The study was designed as a prospective, single-center, uncontrolled study. The recruitment of patients with diabetes type 1 who did not achieve the target values of control of carbohydrate metabolism control, who were on therapy with long-acting and ultrashort-acting analog insulin therapy, was carried out in accordance with the matching criteria. The calculation of TIR and TBR was carried out employing the data from professional continuous monitoring of glucose levels and selfmonitoring of blood glucose levels. The SF-36 Health Status Survey was used to assess QoL.Results. The study included 26 patients who met the inclusion criteria and did not have the exclusion criteria. The relationships between TIR, TBR and QoL parameters during insulin degludec therapy were revealed - with vitality, bodily pain, mental health, which demonstrates an increase in QoL mainly due to the mental component of health.Conclusions. Switching patients with type 1 diabetes from long-acting analog insulins to ultra-long-acting analog insulin on an outpatient basis provides an improvement in glycemic control due to HbA1c and TIR, TBR, and also increases QOL satisfaction, mainly due to the mental component of health.

сахарный диабет 1-го типакачество жизниуровень HbA1cпоказатели времени нахождения в диапазонах гликемииинсулин деглудекdiabetes type 1quality of lifeHbA1cindicators of time in rangesinsulin degludecReferencesШестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А., Дедов И.И. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. 2019;91(10):4–13. https://doi.org/10.26442/00403660.2019.10.000364. Shestakova M.V.,Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Dedov I.I. Diabetes Epidemiology in Russia: What Has Changed over the Decade? Terapevticheskii arkhiv = Therapeutic Archive. 2019;91(10):4–13. (In Russ.) https://doi.org/10.26442/00403660.2019.10.000364.Oriot P., Hermans M.P. “Mind the Gap Please…”: Estimated vs. Measured A1c from Continuous Measurement of interstitial Glucose over a 3-Month Period in Patients with Type 1 Diabetes. Acta clinica Belgica. 2020;75(2):109–115. https://doi.org/10.1080/17843286.2018.1561780.Oriot P., Hermans M.P. “Mind the Gap Please…”: Estimated vs. Measured A1c from Continuous Measurement of interstitial Glucose over a 3-Month Period in Patients with Type 1 Diabetes. Acta clinica Belgica. 2020;75(2):109–115. https://doi.org/10.1080/17843286.2018.1561780.Almagro R.J., Manzanares G.Á., Lucendo A.J., Martínez H.A. Health-Related Quality of Life in Diabetes Mellitus and Its Social, Demographic and Clinical Determinants: A Nationwide Cross-Sectional Survey. J Clin Nurs. 2018;27(21–22):4212–4223. https://doi.org/10.1111/jocn.14624.Almagro R.J., Manzanares G.Á., Lucendo A.J., Martínez H.A. Health-Related Quality of Life in Diabetes Mellitus and Its Social, Demographic and Clinical Determinants: A Nationwide Cross-Sectional Survey. J Clin Nurs. 2018;27(21–22):4212–4223. https://doi.org/10.1111/jocn.14624.Arditi C., Zanchi A., Peytremann-Bridevaux I. Health Status and Quality of Life in Patients with Diabetes in Switzerland. Prim Care Diabetes. 2019;13(3):233–241. https://doi.org/10.1016/j.pcd.2018.11.016.Arditi C., Zanchi A., Peytremann-Bridevaux I. Health Status and Quality of Life in Patients with Diabetes in Switzerland. Prim Care Diabetes. 2019;13(3):233–241. https://doi.org/10.1016/j.pcd.2018.11.016.Al-Taie N., Maftei D., Kautzky-Willer A., Krebs M., Stingl H. Assessing the Quality of Life among Patients with Diabetes in Austria and the Correlation between Glycemic Control and the Quality of Life. Prim Care Diabetes. 2020;14(2):133–138. https://doi.org/10.1016/j.pcd.2019.11.003. 6. Muijs L.T., Racca C., de Wit M., Brouwer A., Wieringa T.H., de Vries R. et al. Glucose Variability and Mood in Adults with Diabetes: A Systematic Review. Endocrinol Diabetes Metab. 2021;14(4):1–11. https://doi.org/10.1002/edm2.152.Al-Taie N., Maftei D., Kautzky-Willer A., Krebs M., Stingl H. Assessing the Quality of Life among Patients with Diabetes in Austria and the Correlation between Glycemic Control and the Quality of Life. Prim Care Diabetes. 2020;14(2):133–138. https://doi.org/10.1016/j.pcd.2019.11.003. 6. Muijs L.T., Racca C., de Wit M., Brouwer A., Wieringa T.H., de Vries R. et al. Glucose Variability and Mood in Adults with Diabetes: A Systematic Review. Endocrinol Diabetes Metab. 2021;14(4):1–11. https://doi.org/10.1002/edm2.152.Reddy M., Godsland I.F., Barnard K.D., Herrero P., Georgiou P., Thomson H. et al. Glycemic Variability and Its Impact on Quality of Life in Adults with Type 1 Diabetes. J Diabetes Sci Technol. 2016;10(1):60–66. https://doi.org/10.1177/1932296815601440.Reddy M., Godsland I.F., Barnard K.D., Herrero P., Georgiou P., Thomson H. et al. Glycemic Variability and Its Impact on Quality of Life in Adults with Type 1 Diabetes. J Diabetes Sci Technol. 2016;10(1):60–66. https://doi.org/10.1177/1932296815601440.Ayano-Takahara S., Ikeda K., Fujimoto S., Hamasaki A., Harashima S.I., Toyoda K. et al. Glycemic Variability Is Associated with Quality of Life and Treatment Satisfaction in Patients with Type 1 Diabetes. Diabetes Care. 2015;38(1):e1–e2. https://doi.org/10.1177/1932296815601440.Ayano-Takahara S., Ikeda K., Fujimoto S., Hamasaki A., Harashima S.I., Toyoda K. et al. Glycemic Variability Is Associated with Quality of Life and Treatment Satisfaction in Patients with Type 1 Diabetes. Diabetes Care. 2015;38(1):e1–e2. https://doi.org/10.1177/1932296815601440.Penckofer S., Quinn L., Byrn M., Ferrans C., Miller M., Strange P. Does Glycemic Variability Impact Mood and Quality of Life? Diabetes Technol Ther. 2012;14(4):303–310. https://doi.org/10.1089/dia.2011.0191.Penckofer S., Quinn L., Byrn M., Ferrans C., Miller M., Strange P. Does Glycemic Variability Impact Mood and Quality of Life? Diabetes Technol Ther. 2012;14(4):303–310. https://doi.org/10.1089/dia.2011.0191.Battelino T., Danne T., Bergenstal R.M., Amiel S.A., Beck R., Biester T. et al. Clinical Targets for continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593–1603. https://doi.org/10.2337/dc17-1600.Battelino T., Danne T., Bergenstal R.M., Amiel S.A., Beck R., Biester T. et al. Clinical Targets for continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593–1603. https://doi.org/10.2337/dc17-1600.Nathan D.M. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care. 2014;37(1):9–16. https://doi.org/10.2337/dc13-2112.Nathan D.M. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care. 2014;37(1):9–16. https://doi.org/10.2337/dc13-2112.Lu J., Ma X., Zhou J., Zhang L., Mo Y., Ying L. et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, with Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care. 2018;41(11):2370–2376. https://doi.org/10.2337/dc18-1131.Lu J., Ma X., Zhou J., Zhang L., Mo Y., Ying L. et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, with Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care. 2018;41(11):2370–2376. https://doi.org/10.2337/dc18-1131.Mayeda L., Katz R., Ahmad I., Bansal N., Batacchi Z., Hirsch I.B. et al. Glucose Time in Range and Peripheral Neuropathy in Type 2 Diabetes Mellitus and Chronic Kidney Disease. BMJ Open. 2020;8(1):1–8. https://doi.org/10.1136/bmjdrc-2019-000991Mayeda L., Katz R., Ahmad I., Bansal N., Batacchi Z., Hirsch I.B. et al. Glucose Time in Range and Peripheral Neuropathy in Type 2 Diabetes Mellitus and Chronic Kidney Disease. BMJ Open. 2020;8(1):1–8. https://doi.org/10.1136/bmjdrc-2019-000991Goldenberg R.M., Aroda V.R., Billings L.K., Christiansen A.S.L., Donatsky A.M., Parvaresh Rizi E. et al. Effect of Insulin Degludec versus Insulin Glargine U100 on Time in Range: SWITCH PRO, a Crossover Study of Basal Insulin‐ treated Adults with Type 2 Diabetes and Risk Factors for Hypoglycaemia. Diabetes Obes Metab. 2021. https://doi.org/10.1111/dom.14504.Goldenberg R.M., Aroda V.R., Billings L.K., Christiansen A.S.L., Donatsky A.M., Parvaresh Rizi E. et al. Effect of Insulin Degludec versus Insulin Glargine U100 on Time in Range: SWITCH PRO, a Crossover Study of Basal Insulin‐ treated Adults with Type 2 Diabetes and Risk Factors for Hypoglycaemia. Diabetes Obes Metab. 2021. https://doi.org/10.1111/dom.14504.Imayama I., Plotnikoff R.C., Courneya K.S., Johnson J.A. Determinants of Quality of Life in Adults with Type 1 and Type 2 Diabetes. Health Qual Life Outcomes. 2011;9(115):1–9. https://doi.org/10.1186/1477-7525-9-115.Imayama I., Plotnikoff R.C., Courneya K.S., Johnson J.A. Determinants of Quality of Life in Adults with Type 1 and Type 2 Diabetes. Health Qual Life Outcomes. 2011;9(115):1–9. https://doi.org/10.1186/1477-7525-9-115.Шишкова Ю.А., Мотовилин О.Г., Дивисенко С.И., Суркова Е.В., Майоров А.Ю. Качество жизни больных сахарным диабетом 1 типа молодого возраста. Сахарный диабет. 2010;13(4):43–47. https://doi.org/10.14341/2072-0351-6056. Shishkova Yu.A., Motovilin O.G., Surkova E.V., Divisenko S.I., Mayorov A.Yu. Quality of Life in Young patients with Type 1 Diabetes Mellitus. Sakharnyy diabet = Diabetes Mellitus. 2010;13(4):43–47. (In Russ.) https://doi.org/10.14341/2072-0351-6056.Шишкова Ю.А., Мотовилин О.Г., Дивисенко С.И., Суркова Е.В., Майоров А.Ю. Качество жизни больных сахарным диабетом 1 типа молодого возраста. Сахарный диабет. 2010;13(4):43–47. https://doi.org/10.14341/2072-0351-6056. Shishkova Yu.A., Motovilin O.G., Surkova E.V., Divisenko S.I., Mayorov A.Yu. Quality of Life in Young patients with Type 1 Diabetes Mellitus. Sakharnyy diabet = Diabetes Mellitus. 2010;13(4):43–47. (In Russ.) https://doi.org/10.14341/2072-0351-6056.Rosenstock J., Dailey G., Massi-Benedetti M., Fritsche A., Lin Z., Salzman A. Reduced Hypoglycemia Risk with Insulin Glargine: A Meta-Analysis Comparing Insulin Glargine with Human NPH Insulin in Type 2 Diabetes. Diabetes Care. 2005;28(4):950–955. https://doi.org/10.2337/diacare.28.4.950.Rosenstock J., Dailey G., Massi-Benedetti M., Fritsche A., Lin Z., Salzman A. Reduced Hypoglycemia Risk with Insulin Glargine: A Meta-Analysis Comparing Insulin Glargine with Human NPH Insulin in Type 2 Diabetes. Diabetes Care. 2005;28(4):950–955. https://doi.org/10.2337/diacare.28.4.950.Mauricio D., Hramiak I. Second-Generation Insulin Analogues – a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons. Eur Endocrinol. 2018; 14(Suppl 1):2–9. https://doi.org/10.17925/ee.2018.14supp1.2.Mauricio D., Hramiak I. Second-Generation Insulin Analogues – a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons. Eur Endocrinol. 2018; 14(Suppl 1):2–9. https://doi.org/10.17925/ee.2018.14supp1.2.Heller S., Mathieu C., Kapur R., Wolden ML., Zinman B. A Meta-Analysis of Rate Ratios for Nocturnal Confirmed Hypoglycaemia with Insulin Degludec vs. Insulin Glargine Using Different Definitions for Hypoglycaemia. Diabet Med. 2016;33(4):478–487. https://doi.org/10.1111/dme.13002.Heller S., Mathieu C., Kapur R., Wolden ML., Zinman B. A Meta-Analysis of Rate Ratios for Nocturnal Confirmed Hypoglycaemia with Insulin Degludec vs. Insulin Glargine Using Different Definitions for Hypoglycaemia. Diabet Med. 2016;33(4):478–487. https://doi.org/10.1111/dme.13002.Zhang X.W., Zhang X.L., Xu B., Kang L.N. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):429–441. https://doi.org/10.1007/s00592-018-1107-1.Zhang X.W., Zhang X.L., Xu B., Kang L.N. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):429–441. https://doi.org/10.1007/s00592-018-1107-1.Lecumberri E., Ortega M., Iturregui M., Quesada J.A., Vázquez C., Orozco D. Quality-of-Life and Treatment Satisfaction in actual Clinical Practice of Patients with Type 1 Diabetes Mellitus (T1DM) and Hypoglycemia Treated with Insulin Degludec. Curr Med Res Opin. 2018;34(6):1053–1059. https://doi.org/10.1080/03007995.2017.1419172.Lecumberri E., Ortega M., Iturregui M., Quesada J.A., Vázquez C., Orozco D. Quality-of-Life and Treatment Satisfaction in actual Clinical Practice of Patients with Type 1 Diabetes Mellitus (T1DM) and Hypoglycemia Treated with Insulin Degludec. Curr Med Res Opin. 2018;34(6):1053–1059. https://doi.org/10.1080/03007995.2017.1419172.Uzoigwe C., Radin M., Hamersky C.M., DeKoven M., Holt C., Karkare S. et al. Quality of Life in Patients with Type 2 Diabetes after Switching to Insulin Degludec: Results from a cross-Sectional Survey. Qual Life Res. 2021;30(6):1629–1640. https://doi.org/10.1007/s11136-020-02753-6.Uzoigwe C., Radin M., Hamersky C.M., DeKoven M., Holt C., Karkare S. et al. Quality of Life in Patients with Type 2 Diabetes after Switching to Insulin Degludec: Results from a cross-Sectional Survey. Qual Life Res. 2021;30(6):1629–1640. https://doi.org/10.1007/s11136-020-02753-6.

The authors declare that there are no conflicts of interest present.